Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids-Reference-Cited by-全球学者库

Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell‐derived organoids

Published:2023-07-20 Issue:25 Volume:14 Page:2591-2600
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thoracic Cancer

Author:

Wu Yuan‐Hung¹²³^ORCID,Chao Heng‐sheng²⁴,Chiang Chi‐Lu²⁴^ORCID,Luo Yung‐Hung²⁴,Chiu Chao‐Hua⁴⁵,Yen Sang‐Hue¹³⁶,Liu Chun‐Yu¹²,Chiou Jeng‐Fong⁷⁸⁹,Burnouf Thierry¹⁰¹¹,Chen Yin‐Ju⁹¹⁰¹¹¹²¹³,Wang Peng‐Yuan¹⁴¹⁵^ORCID,Chao Tsu‐Yi¹⁶¹⁷¹⁸¹⁹,Hsu Shih‐Ming³,Lu Long‐Sheng⁹¹⁰¹¹¹²

Affiliation:

1. Department of Oncology Taipei Veterans General Hospital Taipei Taiwan

2. School of Medicine National Yang‐Ming Chiao‐Tung University Taipei Taiwan

3. Department of Biomedical Imaging and Radiological Sciences National Yang‐Ming Chiao‐Tung University Taipei Taiwan

4. Department of Chest Medicine Taipei Veterans General Hospital Taipei Taiwan

5. Taipei Cancer Center and Taipei Medical University Hospital Taipei Medical University Taipei Taiwan

6. Department of Radiation Oncology Taipei Municipal Wan‐Fang Hospital Taipei Taiwan

7. Department of Radiology, School of Medicine, College of Medicine Taipei Medical University Taipei Taiwan

8. Department of Radiation Oncology Taipei Medical University Taipei Taiwan

9. TMU Research Center of Cancer Translational Medicine Taipei Medical University Taipei Taiwan

10. Graduate Institute of Biomedical Materials and Tissue Engineering, College of Biomedical Engineering Taipei Medical University Taipei Taiwan

11. International Ph.D. Program for Cell Therapy and Regenerative Medicine, College of Medicine Taipei Medical University Taipei Taiwan

12. Department of Radiation Oncology Taipei Medical University Hospital Taipei Taiwan

13. Department of Medical Research Taipei Medical University Taipei Taiwan

14. Oujiang Laboratory Wenzhou China

15. Key Laboratory of Alzheimer's Disease of Zhejiang Province, Institute of Aging Wenzhou Medical University Wenzhou China

16. Graduate Institute of Clinical Medicine, College of Medicine Taipei Medical University Taipei Taiwan

17. Division of Hematology/Oncology, Department of Medicine, Tri‐service General Hospital National Defense Medical Center Taipei Taiwan

18. Division of Hematology and Oncology, Department of Internal Medicine Taipei Medical University‐Shuang Ho Hospital New Taipei City Taiwan

19. Taipei Cancer Center Taipei Medical University Taipei Taiwan

Abstract

AbstractBackgroundSystemic therapy is the primary treatment for advanced thymic malignancies. However, there is an urgent need to improve clinical outcome. Personalized treatment based on predictive biomarkers is a potential approach to address this requirement. In this study, we aimed to show the correlation between drug sensitivity tests on CTCs‐derived organoids and clinical response in patients with thymic malignancies. This approach carries the potential to create personalized cancer avatars and improve treatment outcome for patients.MethodsWe previously reported potential treatment outcome prediction with patient‐derived organoids (cancer avatars) in patients with pancreatic ductal adenocarcinoma. To further investigate the feasibility of this approach in advanced thymic malignancies, we conducted a study in which 12 patients were enrolled and 21 liquid biopsies were performed.ResultsCancer avatars were successfully derived in 16 out of 21 samples (success rate 76.2%). We found a sensitivity of 1.0 and specificity of 0.6 for drug sensitivity tests on the cancer avatars, and a two‐tailed Fisher's exact test revealed a significant correlation between drug sensitivity tests and clinical responses (p = 0.0275).ConclusionThis study supports the potential of circulating tumor cell‐derived organoids to inform personalized treatment for advanced thymic malignancies. Further validation of this proof of concept finding is ongoing.

Funder

Ministry of Science and Technology, Taiwan

National Health Research Institutes

Taipei Medical University

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.15039

Reference29 articles.

1. Epidemiology of Thymoma and Associated Malignancies

2. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.

3. Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma

4. A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207L

5. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers